AI Article Synopsis

  • * The sequencing of tumors has improved understanding of the disease, leading to The Cancer Genome Atlas classification and the start of clinical trials for new treatments targeting various biological pathways.
  • * This review highlights the shift in treatment strategies, focusing on targeted and hormonal therapies as well as immunotherapy for advanced endometrial cancer.

Article Abstract

Until recently, patients diagnosed with locally advanced and metastatic endometrial cancer faced significant challenges in their treatment due to limited options and poor prognostic outcomes. The sequencing of tumors has been a major advancement in its management. It has led to The Cancer Genome Atlas classification currently used in clinical practice and the initiation of several clinical trials for innovative treatments targeting principally signaling pathways, immune checkpoints, DNA integrity, growth factors, hormonal signaling, and metabolism. Numerous clinical trials are investigating a combinatorial approach of these targeted therapies to counter tumoral resistance, cellular compensatory mechanisms, and tumor polyclonality. This review provides a comprehensive overview of historical, current, and promising therapies in advanced and metastatic endometrial cancer. It particularly highlights clinical research on targeted and hormonal therapies, but also immunotherapy, reflecting the evolving landscape of treatment modalities for this disease.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2024.102790DOI Listing

Publication Analysis

Top Keywords

advanced metastatic
12
metastatic endometrial
12
endometrial cancer
12
locally advanced
8
clinical trials
8
cancer
4
cancer current
4
current emerging
4
therapies
4
emerging therapies
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!